Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 18/20 | 0.91 |
| ▸ | SSTR5 | P35346 | 10/20 | 0.91 |
| ▸ | SSTR3 | P32745 | 8/20 | 0.91 |
| ▸ | SSTR4 | P31391 | 8/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ilatreotide SCHEMBL29509152 | 1.00 | SSTR2 (0.91) | SSTR2SSTR5SSTR3SSTR4 | |
| SCHEMBL23901126 | 0.84 | SSTR2 (0.88) | SSTR2SSTR5SSTR3SSTR4 | |
| SCHEMBL23482744 | 0.84 | SSTR2 (0.88) | SSTR2SSTR5SSTR3SSTR4 | |
| SCHEMBL22388803 | 0.83 | SSTR2 (0.87) | SSTR2SSTR5SSTR3SSTR4 | |
| SCHEMBL25504914 | 0.83 | SSTR2 (0.87) | SSTR2SSTR5SSTR3SSTR4 | |
| SCHEMBL22389054 | 0.83 | SSTR2 (0.87) | SSTR2SSTR5SSTR3SSTR4 | |
| Octreotide SCHEMBL21944070 | 0.83 | SSTR2 (1.00) | SSTR2SSTR5SSTR3SSTR4 | |
| Octreotide SCHEMBL21840389 | 0.83 | SSTR2 (1.00) | SSTR2SSTR5SSTR3SSTR4 | |
| Octreotide SCHEMBL23424109 | 0.83 | SSTR2 (1.00) | SSTR2SSTR5SSTR3SSTR4 | |
| Octreotide SCHEMBL17404479 | 0.83 | SSTR2 (1.00) | SSTR2SSTR5SSTR3SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-12605447-B2 | Stable formulations for radionuclide complexes | ITM SOLUCIN GMBH (DE) | 2026-04-21 | — | — | US | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-12491272-B2 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2025-12-09 | — | — | US | disclosed |
| US-20250345468-A1 | COMBINATION TREATMENT OF SMALL-CELL LUNG CANCER | ITM ISOTOPE TECH MUNICH SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250332301-A1 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4640241-A2 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | Advanced Accelerator Applications S.A. (FR) | 2025-10-29 | — | — | EP | disclosed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | disclosed |
| WO-2010024870-A1 | SKIN-CONTACTING-ADHESIVE FREE DRESSING | JENNINGS-SPRING BARBARA BROOKE (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20090005722-A1 | Skin-contacting-adhesive free dressing | JENNLNGS-SPRING BARBARA | 2009-01-01 | — | — | US | disclosed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | disclosed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345468-A1 | COMBINATION TREATMENT OF SMALL-CELL LUNG CANCER | SSTR1, SSTR3, SSTR2 | SSTR2 3/4885SSTR5 4/4885SSTR3 2/4885 |
| US-20250332301-A1 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | RAB5IF, TMEM14C, PAICS | SSTR2 418/4885SSTR5 164/4885SSTR3 241/4885 |
| US-12605447-B2 | Stable formulations for radionuclide complexes | EPOR, CD47, PRCP | SSTR2 15/4885SSTR5 14/4885SSTR3 19/4885 |
| US-12491272-B2 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | SSTR2 461/4885SSTR5 188/4885SSTR3 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.